Evotec AG’s EVT 101 Well Tolerated in Four Week Higher Repeat Dose Safety Study

HAMBURG, Germany, July 3, 2008 (PRIME NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC) announced today top-line results of a double-blind, 4-week Phase Ib study with EVT 101, an orally active NR2B-subtype selective antagonist of NMDA receptors with potential in Alzheimer’s disease, neuropathic pain and other indications. The study showed in both young and elderly subjects that the drug was well tolerated up to the highest dose tested.

MORE ON THIS TOPIC